Integra LifeSciences initiated a recall on 23 May of all products manufactured at its Boston facility distributed between 1 March 2018 and 22 May of this year. The company initiated the recall, which includes the surgical repair products SurgiMend, PriMatrix, Revize, and TissueMend, because of endotoxin deviations that could result in higher levels of toxins in the products than are permitted. Higher endotoxins can result in post-operative fever.
The voluntary recall, according to analysis from Wells Fargo, could cost the company some $22m in impairment charges that it plans to record in the quarter ending 30 June....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?